Pharmaceuticals

Companies carrying out pharmaceutical research will be aware of patent protection, but perhaps less so of other forms of intellectual property rights (IPRs) that compliment patents. Supplementary Protection Certificates (SPCs) are linked to a granted patent, and are available across Europe. Once granted, SPCs provide additional protection for a marketable...

As part of the UK Government’s strategy to rebound the economy through the success of knowledge-led high skill businesses, the UK Intellectual Property Office (UKIPO) has launched a new IP Access fund as an extension of the existing IP Audit Plus programme. This new fund, which offers grants of up...

  Opposition proceedings at the EPO provide a time-limited opportunity for a third party to challenge the validity of a granted European patent centrally, with the aim of achieving revocation, or at least a limitation, of the granted patent rights. In this article, we will give an overview of the...

  Our article ‘Patenting Biological Simulations in Drug Discovery’ has been published in Drug Discovery Today, by Elsevier. It examines the challenges faced when pursuing patent protection for biological simulations, particularly in view of the guidance provided by the European Patent Office in G1/19. Article Highlights: Biological simulations typically require...

  It is just over four years since Board 3.3.01 of the EPO Boards of Appeal delivered its much-anticipated decision in the Dasatinib case (T 488/16). Having been closely involved in that case on behalf of one of the opponents, it was obvious to me that the decision represented a...